158 related articles for article (PubMed ID: 34337093)
21. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
Sarwar S; Tarique S; Aleem A; Khan AA
Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1035-1039. PubMed ID: 31274596
[TBL] [Abstract][Full Text] [Related]
22. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
Pott-Junior H; Bricks G; Grandi G; Figueiredo Senise J; Castelo Filho A
Clin Microbiol Infect; 2019 Mar; 25(3):365-371. PubMed ID: 29906601
[TBL] [Abstract][Full Text] [Related]
23. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
Yousif MM; Ahmed H; Elsadek HM; Shendi AM; Gouda TM; Elsayed IA; Gendia MA; Magdy MM; Lbrahim NF; Sadek AMEM; Zaki AM; Shafeik H; Zahran MH
J Viral Hepat; 2020 Nov; 27(11):1190-1201. PubMed ID: 32564500
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
[TBL] [Abstract][Full Text] [Related]
25. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
Mangia A; Arleo A; Copetti M; Miscio M; Piazzolla V; Santoro R; Squillante MM
Liver Int; 2016 Jul; 36(7):971-6. PubMed ID: 26786792
[TBL] [Abstract][Full Text] [Related]
26. Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Mangia A; Losappio R; Cenderello G; Potenza D; Mazzola M; De Stefano G; Terreni N; Copetti M; Minerva N; Piazzola V; Bacca D; Palmieri V; Sogari F; Santoro R
PLoS One; 2018; 13(7):e0200568. PubMed ID: 30063745
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
Mei YY; Chen YM; Wu YK; Zhang XH; Xu WX
Can J Gastroenterol Hepatol; 2020; 2020():8872120. PubMed ID: 33194875
[TBL] [Abstract][Full Text] [Related]
28. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy.
Iio E; Shimada N; Takaguchi K; Senoh T; Eguchi Y; Atsukawa M; Tsubota A; Abe H; Kato K; Kusakabe A; Miyaki T; Matsuura K; Matsunami K; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
Hepatol Res; 2017 Nov; 47(12):1308-1316. PubMed ID: 28332272
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
30. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Nelson DR; Cooper JN; Lalezari JP; Lawitz E; Pockros PJ; Gitlin N; Freilich BF; Younes ZH; Harlan W; Ghalib R; Oguchi G; Thuluvath PJ; Ortiz-Lasanta G; Rabinovitz M; Bernstein D; Bennett M; Hawkins T; Ravendhran N; Sheikh AM; Varunok P; Kowdley KV; Hennicken D; McPhee F; Rana K; Hughes EA;
Hepatology; 2015 Apr; 61(4):1127-35. PubMed ID: 25614962
[TBL] [Abstract][Full Text] [Related]
31. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Sulkowski MS; Flamm S; Kayali Z; Lawitz EJ; Kwo P; McPhee F; Torbeyns A; Hughes EA; Swenson ES; Yin PD; Linaberry M
Liver Int; 2017 Jun; 37(6):836-842. PubMed ID: 27943563
[TBL] [Abstract][Full Text] [Related]
32. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
Wu SH; Chu CJ; Su CW; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2019 Sep; 82(9):693-698. PubMed ID: 31356562
[TBL] [Abstract][Full Text] [Related]
33. [Safety and efficacy of DCV-based DAAs therapy for chronic HCV infection in China].
Wei JY; Lin DN; Wu ZB; Zhu JY; Zhao ZX; Mei YY; Lin CS; Zhang J; Zhang XH
Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):933-939. PubMed ID: 30669787
[No Abstract] [Full Text] [Related]
34. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
36. Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
McPhee F; Hernandez D; Zhou N
Antivir Ther; 2017; 22(3):237-246. PubMed ID: 28008868
[TBL] [Abstract][Full Text] [Related]
37. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
[TBL] [Abstract][Full Text] [Related]
38. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
[TBL] [Abstract][Full Text] [Related]
39. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
40. Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study.
Sacco R; Messina V; Gentilucci UV; Adinolfi LE; Ascione A; Barbarini G; Barlattani A; Cariti G; Cozzolongo R; Fimiani B; Francavilla R; Furlan C; Garrucciu G; Iovinella V; Rinaldi L; Marignani M; Begini P; Palitti VP; Pellicelli AM; Scifo G; Facciorusso A; Giacomelli L; Shah A; Bertino G; Perazzo S; Bresci G; Izzi A
Drugs Context; 2020; 9():. PubMed ID: 33408749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
